JP2014533734A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014533734A5 JP2014533734A5 JP2014543732A JP2014543732A JP2014533734A5 JP 2014533734 A5 JP2014533734 A5 JP 2014533734A5 JP 2014543732 A JP2014543732 A JP 2014543732A JP 2014543732 A JP2014543732 A JP 2014543732A JP 2014533734 A5 JP2014533734 A5 JP 2014533734A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- group
- hydroxybenzamide
- benzamide
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 40
- -1 8-methyl-6,7,8,9-tetrahydropyrido [3 ', 2': 4,5] pyrrolo [1,2-c] pyrimidin-5-yl Chemical group 0.000 claims 16
- 125000001072 heteroaryl group Chemical group 0.000 claims 14
- 125000000623 heterocyclic group Chemical group 0.000 claims 14
- 125000003118 aryl group Chemical group 0.000 claims 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 7
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 229910052717 sulfur Inorganic materials 0.000 claims 5
- 125000002877 alkyl aryl group Chemical group 0.000 claims 4
- 125000002947 alkylene group Chemical group 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000001931 aliphatic group Chemical group 0.000 claims 3
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- XXUNIGZDNWWYED-UHFFFAOYSA-N 2-methylbenzamide Chemical compound CC1=CC=CC=C1C(N)=O XXUNIGZDNWWYED-UHFFFAOYSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- ZXNBWIADYUMAAH-UHFFFAOYSA-N n-sulfanylbenzamide Chemical compound SNC(=O)C1=CC=CC=C1 ZXNBWIADYUMAAH-UHFFFAOYSA-N 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 1
- BJZWUQXOJCYIOO-UHFFFAOYSA-N 4-[(2,6-dimethyl-5-oxo-7,8-dihydrothieno[2,3]pyrrolo[4,5-b]pyrazin-4-yl)sulfanyl]-n-hydroxybenzamide Chemical compound O=C1N(C)CCN(C=2C=C(C)SC=22)C1=C2SC1=CC=C(C(=O)NO)C=C1 BJZWUQXOJCYIOO-UHFFFAOYSA-N 0.000 claims 1
- SNTTVCXKAZIJCC-UHFFFAOYSA-N 4-[(2,6-dimethyl-5-oxo-7,8-dihydrothieno[3,4]pyrrolo[1,3-c]pyridin-4-yl)methyl]-n-hydroxybenzamide Chemical compound O=C1N(C)CCC(C=2SC(C)=CC=22)=C1N2CC1=CC=C(C(=O)NO)C=C1 SNTTVCXKAZIJCC-UHFFFAOYSA-N 0.000 claims 1
- WIPUVTJEFBVRFM-UHFFFAOYSA-N 4-[(2,6-dimethyl-5-oxo-7,8-dihydrothieno[3,4]pyrrolo[3,5-b]pyrazin-4-yl)methyl]-n-hydroxybenzamide Chemical compound O=C1N(C)CCN(C=2C=C(C)SC=22)C1=C2CC1=CC=C(C(=O)NO)C=C1 WIPUVTJEFBVRFM-UHFFFAOYSA-N 0.000 claims 1
- BDOLTQSBVSUXLN-UHFFFAOYSA-N 4-[(2,6-dimethyl-7,8-dihydro-5h-thieno[2,3]pyrrolo[4,5-a]pyrazin-4-yl)sulfanyl]-n-hydroxybenzamide Chemical compound C1N(C)CCN(C=2C=C(C)SC=22)C1=C2SC1=CC=C(C(=O)NO)C=C1 BDOLTQSBVSUXLN-UHFFFAOYSA-N 0.000 claims 1
- RKHFAVMOGRTFLO-UHFFFAOYSA-N 4-[(2,6-dimethyl-7,8-dihydro-5h-thieno[3,4]pyrrolo[1,3-a]pyridin-4-yl)methyl]-n-hydroxybenzamide Chemical compound C1N(C)CCC(C=2SC(C)=CC=22)=C1N2CC1=CC=C(C(=O)NO)C=C1 RKHFAVMOGRTFLO-UHFFFAOYSA-N 0.000 claims 1
- XLHUSHZTQIMOPD-UHFFFAOYSA-N 4-[(2,6-dimethyl-7-oxo-5,8-dihydrothieno[3,4]pyrrolo[1,3-b]pyridin-4-yl)methyl]-n-hydroxybenzamide Chemical compound C1C(=O)N(C)CC2=C1C=1SC(C)=CC=1N2CC1=CC=C(C(=O)NO)C=C1 XLHUSHZTQIMOPD-UHFFFAOYSA-N 0.000 claims 1
- FDPQIRJFFJJTOA-UHFFFAOYSA-N 4-[(2,7-dimethyl-3,4-dihydro-1h-pyrimido[1,6-a]indol-5-yl)sulfanyl]-n-hydroxybenzamide Chemical compound C12=CC(C)=CC=C2N2CN(C)CCC2=C1SC1=CC=C(C(=O)NO)C=C1 FDPQIRJFFJJTOA-UHFFFAOYSA-N 0.000 claims 1
- XVJCHEQHYVFYCA-UHFFFAOYSA-N 4-[(2,7-dimethyl-3,4-dihydro-1h-thieno[2,3]pyrrolo[4,5-a]pyrimidin-5-yl)sulfanyl]-n-hydroxybenzamide Chemical compound C1=2SC(C)=CC=2N2CN(C)CCC2=C1SC1=CC=C(C(=O)NO)C=C1 XVJCHEQHYVFYCA-UHFFFAOYSA-N 0.000 claims 1
- LSBLBWWAQCDZPQ-UHFFFAOYSA-N 4-[(2,7-dimethyl-3,4-dihydro-1h-thieno[3,4]pyrrolo[3,5-a]pyrimidin-5-yl)methyl]-n-hydroxybenzamide Chemical compound C1=2SC(C)=CC=2N2CN(C)CCC2=C1CC1=CC=C(C(=O)NO)C=C1 LSBLBWWAQCDZPQ-UHFFFAOYSA-N 0.000 claims 1
- HIYBAUVHLIZOPB-UHFFFAOYSA-N 4-[(2,7-dimethyl-6,8-dihydro-5h-thieno[3,4]pyrrolo[1,3-a]pyridin-4-yl)methyl]-n-hydroxybenzamide Chemical compound C1N(C)CCC2=C1C=1SC(C)=CC=1N2CC1=CC=C(C(=O)NO)C=C1 HIYBAUVHLIZOPB-UHFFFAOYSA-N 0.000 claims 1
- YMTGNKYUXYSKDQ-UHFFFAOYSA-N 4-[(2,7-dimethyl-6-oxo-5,8-dihydrothieno[3,4]pyrrolo[1,3-b]pyridin-4-yl)methyl]-n-hydroxybenzamide Chemical compound C1C(=O)N(C)CC(C=2SC(C)=CC=22)=C1N2CC1=CC=C(C(=O)NO)C=C1 YMTGNKYUXYSKDQ-UHFFFAOYSA-N 0.000 claims 1
- AJFRVSYCPIIEEJ-UHFFFAOYSA-N 4-[(2,7-dimethyl-8-oxo-5,6-dihydrothieno[3,4]pyrrolo[1,3-c]pyridin-4-yl)methyl]-n-hydroxybenzamide Chemical compound O=C1N(C)CCC2=C1C=1SC(C)=CC=1N2CC1=CC=C(C(=O)NO)C=C1 AJFRVSYCPIIEEJ-UHFFFAOYSA-N 0.000 claims 1
- USFVEXAZWNPRQQ-UHFFFAOYSA-N 4-[(2,8-dimethyl-1-oxo-3,4-dihydropyrazino[1,2-a]indol-10-yl)sulfanyl]-n-hydroxybenzamide Chemical compound O=C1N(C)CCN(C2=CC=C(C)C=C22)C1=C2SC1=CC=C(C(=O)NO)C=C1 USFVEXAZWNPRQQ-UHFFFAOYSA-N 0.000 claims 1
- OHMVZRLVJOILTI-UHFFFAOYSA-N 4-[(2,8-dimethyl-3,4-dihydro-1h-pyrazino[1,2-a]indol-10-yl)sulfanyl]-n-hydroxybenzamide Chemical compound C1N(C)CCN(C2=CC=C(C)C=C22)C1=C2SC1=CC=C(C(=O)NO)C=C1 OHMVZRLVJOILTI-UHFFFAOYSA-N 0.000 claims 1
- XJGXASIKXMDQTC-UHFFFAOYSA-N 4-[(2,8-dimethyl-3,4-dihydro-1h-pyrimido[1,6-a]indol-5-yl)sulfanyl]-n-hydroxybenzamide Chemical compound C12=CC=C(C)C=C2N2CN(C)CCC2=C1SC1=CC=C(C(=O)NO)C=C1 XJGXASIKXMDQTC-UHFFFAOYSA-N 0.000 claims 1
- RXRSAKMLYOLAOQ-UHFFFAOYSA-N 4-[(6,8-difluoro-2-methyl-1-oxo-3,4-dihydropyrazino[1,2-a]indol-10-yl)methyl]-n-hydroxybenzamide Chemical compound O=C1N(C)CCN(C2=C(F)C=C(F)C=C22)C1=C2CC1=CC=C(C(=O)NO)C=C1 RXRSAKMLYOLAOQ-UHFFFAOYSA-N 0.000 claims 1
- LIPOKVQTTQWJBZ-UHFFFAOYSA-N 4-[(6,8-difluoro-2-methyl-1-oxo-3,4-dihydropyrazino[1,2-a]indol-10-yl)sulfanyl]-n-hydroxybenzamide Chemical compound O=C1N(C)CCN(C2=C(F)C=C(F)C=C22)C1=C2SC1=CC=C(C(=O)NO)C=C1 LIPOKVQTTQWJBZ-UHFFFAOYSA-N 0.000 claims 1
- NUJIYAIVNNMYCX-UHFFFAOYSA-N 4-[(6,8-difluoro-2-methyl-3,4-dihydro-1h-pyrazino[1,2-a]indol-10-yl)methyl]-n-hydroxybenzamide Chemical compound C1N(C)CCN(C2=C(F)C=C(F)C=C22)C1=C2CC1=CC=C(C(=O)NO)C=C1 NUJIYAIVNNMYCX-UHFFFAOYSA-N 0.000 claims 1
- WEEKLFUXFYOMIY-UHFFFAOYSA-N 4-[(6,8-difluoro-2-methyl-3,4-dihydro-1h-pyrazino[1,2-a]indol-10-yl)sulfanyl]-n-hydroxybenzamide Chemical compound C1N(C)CCN(C2=C(F)C=C(F)C=C22)C1=C2SC1=CC=C(C(=O)NO)C=C1 WEEKLFUXFYOMIY-UHFFFAOYSA-N 0.000 claims 1
- BZOISYCHWUPRJQ-UHFFFAOYSA-N 4-[(6-chloro-8-fluoro-2-methyl-3,4-dihydro-1h-pyrazino[1,2-a]indol-10-yl)sulfanyl]-n-hydroxybenzamide Chemical compound C1N(C)CCN(C2=C(Cl)C=C(F)C=C22)C1=C2SC1=CC=C(C(=O)NO)C=C1 BZOISYCHWUPRJQ-UHFFFAOYSA-N 0.000 claims 1
- ZTSAYBNKQCCSAX-UHFFFAOYSA-N 4-[(6-fluoro-2-methyl-3,4-dihydro-1h-pyrazino[1,2-a]indol-10-yl)sulfanyl]-n-hydroxybenzamide Chemical compound C1N(C)CCN(C2=C(F)C=CC=C22)C1=C2SC1=CC=C(C(=O)NO)C=C1 ZTSAYBNKQCCSAX-UHFFFAOYSA-N 0.000 claims 1
- GUNPKRHQCCJCMD-UHFFFAOYSA-N 4-[(7,9-difluoro-2-methyl-3,4-dihydro-1h-pyrimido[1,6-a]indol-5-yl)methyl]-n-hydroxybenzamide Chemical compound C12=CC(F)=CC(F)=C2N2CN(C)CCC2=C1CC1=CC=C(C(=O)NO)C=C1 GUNPKRHQCCJCMD-UHFFFAOYSA-N 0.000 claims 1
- KTVOQZFSVYOGNU-UHFFFAOYSA-N 4-[(7-chloro-2-methyl-3,4-dihydro-1h-pyrimido[1,6-a]indol-5-yl)methyl]-n-hydroxybenzamide Chemical compound C12=CC(Cl)=CC=C2N2CN(C)CCC2=C1CC1=CC=C(C(=O)NO)C=C1 KTVOQZFSVYOGNU-UHFFFAOYSA-N 0.000 claims 1
- YLOGSTFIZFTMPG-UHFFFAOYSA-N 4-[(7-chloro-2-methyl-3,4-dihydro-1h-pyrimido[1,6-a]indol-5-yl)sulfanyl]-n-hydroxybenzamide Chemical compound C12=CC(Cl)=CC=C2N2CN(C)CCC2=C1SC1=CC=C(C(=O)NO)C=C1 YLOGSTFIZFTMPG-UHFFFAOYSA-N 0.000 claims 1
- VRUNZOZCEQFNHX-UHFFFAOYSA-N 4-[(7-chloro-9-fluoro-2-methyl-3,4-dihydro-1h-pyrimido[1,6-a]indol-5-yl)methyl]-n-hydroxybenzamide Chemical compound C12=CC(Cl)=CC(F)=C2N2CN(C)CCC2=C1CC1=CC=C(C(=O)NO)C=C1 VRUNZOZCEQFNHX-UHFFFAOYSA-N 0.000 claims 1
- QDWRHMMYPOVKIV-UHFFFAOYSA-N 4-[(7-fluoro-2-methyl-3,4-dihydro-1h-pyrimido[1,6-a]indol-5-yl)methyl]-n-hydroxybenzamide Chemical compound C12=CC(F)=CC=C2N2CN(C)CCC2=C1CC1=CC=C(C(=O)NO)C=C1 QDWRHMMYPOVKIV-UHFFFAOYSA-N 0.000 claims 1
- QSIYARITHJLOEC-UHFFFAOYSA-N 4-[(7-fluoro-2-methyl-3,4-dihydro-1h-pyrimido[1,6-a]indol-5-yl)sulfanyl]-n-hydroxybenzamide Chemical compound C12=CC(F)=CC=C2N2CN(C)CCC2=C1SC1=CC=C(C(=O)NO)C=C1 QSIYARITHJLOEC-UHFFFAOYSA-N 0.000 claims 1
- YNYRCMXFALCJOV-UHFFFAOYSA-N 4-[(8-chloro-2-methyl-1-oxo-3,4-dihydropyrazino[1,2-a]indol-10-yl)sulfanyl]-n-hydroxybenzamide Chemical compound O=C1N(C)CCN(C2=CC=C(Cl)C=C22)C1=C2SC1=CC=C(C(=O)NO)C=C1 YNYRCMXFALCJOV-UHFFFAOYSA-N 0.000 claims 1
- UFYUKJGSUPVSCJ-UHFFFAOYSA-N 4-[(8-chloro-2-methyl-3,4-dihydro-1h-pyrazino[1,2-a]indol-10-yl)sulfanyl]-n-hydroxybenzamide Chemical compound C1N(C)CCN(C2=CC=C(Cl)C=C22)C1=C2SC1=CC=C(C(=O)NO)C=C1 UFYUKJGSUPVSCJ-UHFFFAOYSA-N 0.000 claims 1
- KGEPMMSNKGJUBR-UHFFFAOYSA-N 4-[(8-chloro-2-methyl-3,4-dihydro-1h-pyrimido[1,6-a]indol-5-yl)sulfanyl]-n-hydroxybenzamide Chemical compound C12=CC=C(Cl)C=C2N2CN(C)CCC2=C1SC1=CC=C(C(=O)NO)C=C1 KGEPMMSNKGJUBR-UHFFFAOYSA-N 0.000 claims 1
- COALSBOYMKRDGE-UHFFFAOYSA-N 4-[(8-chloro-6-fluoro-2-methyl-1-oxo-3,4-dihydropyrazino[1,2-a]indol-10-yl)sulfanyl]-n-hydroxybenzamide Chemical compound O=C1N(C)CCN(C2=C(F)C=C(Cl)C=C22)C1=C2SC1=CC=C(C(=O)NO)C=C1 COALSBOYMKRDGE-UHFFFAOYSA-N 0.000 claims 1
- AMBPUDKKEYVJFH-UHFFFAOYSA-N 4-[(8-fluoro-2-methyl-1-oxo-3,4-dihydropyrazino[1,2-a]indol-10-yl)methyl]-n-hydroxybenzamide Chemical compound O=C1N(C)CCN(C2=CC=C(F)C=C22)C1=C2CC1=CC=C(C(=O)NO)C=C1 AMBPUDKKEYVJFH-UHFFFAOYSA-N 0.000 claims 1
- QGLXUZYILJZVCH-UHFFFAOYSA-N 4-[(8-fluoro-2-methyl-1-oxo-3,4-dihydropyrazino[1,2-a]indol-10-yl)sulfanyl]-n-hydroxybenzamide Chemical compound O=C1N(C)CCN(C2=CC=C(F)C=C22)C1=C2SC1=CC=C(C(=O)NO)C=C1 QGLXUZYILJZVCH-UHFFFAOYSA-N 0.000 claims 1
- QYFUFDXSMWFHPI-UHFFFAOYSA-N 4-[(8-fluoro-2-methyl-3,4-dihydro-1h-pyrazino[1,2-a]indol-10-yl)sulfanyl]-n-hydroxybenzamide Chemical compound C1N(C)CCN(C2=CC=C(F)C=C22)C1=C2SC1=CC=C(C(=O)NO)C=C1 QYFUFDXSMWFHPI-UHFFFAOYSA-N 0.000 claims 1
- OLHMEPJAFQYIOV-UHFFFAOYSA-N 4-[(8-fluoro-2-methyl-3,4-dihydro-1h-pyrimido[1,6-a]indol-5-yl)sulfanyl]-n-hydroxybenzamide Chemical compound C12=CC=C(F)C=C2N2CN(C)CCC2=C1SC1=CC=C(C(=O)NO)C=C1 OLHMEPJAFQYIOV-UHFFFAOYSA-N 0.000 claims 1
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 229940079156 Proteasome inhibitor Drugs 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 125000004450 alkenylene group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 125000005275 alkylenearyl group Chemical group 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 239000003080 antimitotic agent Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 125000005110 aryl thio group Chemical group 0.000 claims 1
- 125000000732 arylene group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000004405 heteroalkoxy group Chemical group 0.000 claims 1
- 125000005549 heteroarylene group Chemical group 0.000 claims 1
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 1
- 125000005368 heteroarylthio group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- OICQBETVRGJDBF-UHFFFAOYSA-N n-hydroxy-4-(2-methyl-3,4-dihydro-1h-pyrimido[1,6-a]indole-5-carbonyl)benzamide Chemical compound C12=CC=CC=C2N2CN(C)CCC2=C1C(=O)C1=CC=C(C(=O)NO)C=C1 OICQBETVRGJDBF-UHFFFAOYSA-N 0.000 claims 1
- CZOAHLAHJFJMSO-UHFFFAOYSA-N n-hydroxy-4-[(2-methyl-3,4-dihydro-1h-pyrimido[1,6-a]indol-5-yl)methyl]benzamide Chemical compound C12=CC=CC=C2N2CN(C)CCC2=C1CC1=CC=C(C(=O)NO)C=C1 CZOAHLAHJFJMSO-UHFFFAOYSA-N 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 239000003207 proteasome inhibitor Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161629827P | 2011-11-29 | 2011-11-29 | |
| US61/629,827 | 2011-11-29 | ||
| PCT/CA2012/001101 WO2013078544A1 (en) | 2011-11-29 | 2012-11-29 | Heterocyclic amides compounds which are hdac6 inhibitors and used as anti-tumoral agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014533734A JP2014533734A (ja) | 2014-12-15 |
| JP2014533734A5 true JP2014533734A5 (enExample) | 2016-01-21 |
| JP6272773B2 JP6272773B2 (ja) | 2018-01-31 |
Family
ID=48534555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014543732A Expired - Fee Related JP6272773B2 (ja) | 2011-11-29 | 2012-11-29 | Ｈｄａｃ６阻害剤・抗腫瘍剤用複素環アミド化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9345905B2 (enExample) |
| EP (1) | EP2785720B1 (enExample) |
| JP (1) | JP6272773B2 (enExample) |
| CN (1) | CN103974956B (enExample) |
| CA (1) | CA2857193A1 (enExample) |
| WO (1) | WO2013078544A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2451686C1 (ru) * | 2010-12-27 | 2012-05-27 | Александр Васильевич Иващенко | ЗАМЕЩЕННЫЕ ГИДРИРОВАННЫЕ ТИЕНО-ПИРРОЛО [3,2-c] ПИРИДИНЫ, ЛИГАНДЫ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ИХ ПРИМЕНЕНИЯ |
| HRP20181965T1 (hr) * | 2013-12-12 | 2019-02-08 | Chong Kun Dang Pharmaceutical Corp. | Novi derivati azaindola kao selektivni inhibitori histonske deacetilaze (hdac) i farmaceutski pripravci koji ih sadrže |
| KR101685639B1 (ko) * | 2014-01-03 | 2016-12-12 | 주식회사 종근당 | 신규한 인돌 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
| JP6757312B2 (ja) | 2014-03-27 | 2020-09-16 | ヴァンダービルト ユニバーシティー | 置換インドールｍｃｌ−１阻害剤 |
| WO2016020369A1 (en) * | 2014-08-04 | 2016-02-11 | Universität Regensburg | Novel hdac6 inhibitors and their uses |
| PL3330259T3 (pl) | 2015-07-27 | 2021-02-08 | Chong Kun Dang Pharmaceutical Corp. | Związek pochodna amidowa 1,3,4-oksadiazolu jako inhibitor deacetylazy histonowej 6 i kompozycja farmaceutyczna go zawierająca |
| US10464911B2 (en) | 2015-07-27 | 2019-11-05 | Chong Kun Dang Pharmaceutical Corp. | 1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
| ES2935932T3 (es) | 2015-07-27 | 2023-03-13 | Chong Kun Dang Pharmaceutical Corp | Compuestos de derivados de 1,3,4-oxadiazolsulfonamida como inhibidor de histona desacetilasa 6, y la composición farmacéutica que comprende los mismos |
| EP3331864B1 (en) * | 2015-08-04 | 2021-11-03 | Chong Kun Dang Pharmaceutical Corp. | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
| MX384527B (es) | 2015-10-12 | 2025-03-14 | Chong Kun Dang Pharmaceutical Corp | Compuestos derivados de oxadiazolamina como inhibidores de histona desacetilasa 6, y la composición farmacéutica que comprende los mismos |
| AU2017228385B2 (en) * | 2016-03-04 | 2021-11-04 | Vanderbilt University | Substituted indole Mcl-1 inhibitors |
| EP3532054A4 (en) * | 2016-10-28 | 2020-06-17 | Acetylon Pharmaceuticals, Inc. | PHARMACEUTICAL COMBINATIONS WITH A HISTONE DEACETYLASE INHIBITOR AND EPOTHILON AND METHOD FOR USE THEREOF |
| US11535598B2 (en) | 2017-05-16 | 2022-12-27 | Annji Pharmaceutical Co., Ltd. | Histone deacetylases (HDACs) inhibitors |
| KR20190043437A (ko) | 2017-10-18 | 2019-04-26 | 씨제이헬스케어 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물 |
| KR102316234B1 (ko) | 2018-07-26 | 2021-10-22 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
| KR102195348B1 (ko) | 2018-11-15 | 2020-12-24 | 에이치케이이노엔 주식회사 | 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물 |
| AU2020284606B2 (en) | 2019-05-31 | 2023-01-19 | Chong Kun Dang Pharmaceutical Corp. | 1,3,4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
| WO2021127643A1 (en) | 2019-12-20 | 2021-06-24 | Tenaya Therapeutics, Inc. | Fluoroalkyl-oxadiazoles and uses thereof |
| CA3215958A1 (en) | 2021-04-23 | 2022-10-27 | Tenaya Therapeutics, Inc. | Hdac6 inhibitors for use in the treatment of dilated cardiomyopathy |
| US20240252502A1 (en) | 2021-05-04 | 2024-08-01 | Tenaya Therapeutics, Inc. | Hdac6 inhibitors for treatment of metabolic disease and hfpef |
| CN113861193A (zh) * | 2021-11-04 | 2021-12-31 | 西南大学 | 一种光引发自由基串联反应制备吲哚并四氢吡啶二酮及其衍生物的方法和产品 |
| WO2025215092A1 (en) | 2024-04-10 | 2025-10-16 | Institut National de la Santé et de la Recherche Médicale | Selective hdac6 inhibitors for use in the treatment of myotonic dystrophy type 1 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006063294A2 (en) * | 2004-12-09 | 2006-06-15 | Kalypsys, Inc. | Novel inhibitors of histone deacetylase for the treatment of disease |
| CA2597193A1 (en) * | 2007-08-13 | 2009-02-13 | De Montfort University | Compounds and uses |
| WO2009026446A2 (en) * | 2007-08-21 | 2009-02-26 | Arqule, Inc. | Hdac inhibitors |
| CA2703718A1 (en) * | 2007-11-02 | 2009-05-07 | Tammy Mallais | Inhibitors of histone deacetylase |
| EP2227233B1 (en) * | 2007-11-30 | 2013-02-13 | Newlink Genetics | Ido inhibitors |
| ES2588193T3 (es) * | 2008-03-28 | 2016-10-31 | Nerviano Medical Sciences S.R.L. | Derivados de 3,4-dihidro-2H-pirazino[1,2-a]indol-1-ona activos como inhibidores de cinasa, proceso para su preparación y composiciones farmacéuticas que los comprenden |
| EP2424364A4 (en) * | 2009-04-29 | 2012-12-19 | Medivation Technologies Inc | PYRIDO [4.3-B] INDOLES AND METHODS OF USE |
| JP5827943B2 (ja) | 2009-04-29 | 2015-12-02 | メディベイション テクノロジーズ， インコーポレイテッド | ピリド［４，３−ｂ］インドールおよびその使用方法 |
| JP5838157B2 (ja) | 2009-07-22 | 2015-12-24 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイＴｈｅ Ｂｏａｒｄ Ｏｆ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｉｌｌｉｎｏｉｓ | Ｈｄａｃ阻害剤およびそれを用いる治療法 |
| US20110053925A1 (en) * | 2009-08-28 | 2011-03-03 | Novartis Ag | Hydroxamate-Based Inhibitors of Deacetylases |
| IT1396915B1 (it) * | 2009-10-23 | 2012-12-20 | Italfarmaco Spa | Dietil-[6-(4-idrossicarbamoil-fenil-carbamoilossimetil)-naftalen-2-il-metil]-ammonio cloruro ed altri derivati della n-idrossi-benzammide per l'uso nel trattamento di infezioni da hiv. |
| CN103906732A (zh) * | 2011-10-28 | 2014-07-02 | 株式会社钟根堂 | 用作hdac抑制剂的异羟肟酸酯衍生物以及包含所述衍生物的药物组合物 |
-
2012
- 2012-11-29 CA CA2857193A patent/CA2857193A1/en not_active Abandoned
- 2012-11-29 CN CN201280058930.1A patent/CN103974956B/zh not_active Expired - Fee Related
- 2012-11-29 EP EP12854213.1A patent/EP2785720B1/en not_active Not-in-force
- 2012-11-29 WO PCT/CA2012/001101 patent/WO2013078544A1/en not_active Ceased
- 2012-11-29 US US14/361,278 patent/US9345905B2/en not_active Expired - Fee Related
- 2012-11-29 JP JP2014543732A patent/JP6272773B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014533734A5 (enExample) | ||
| JP2013544261A5 (enExample) | ||
| JP2017503867A5 (enExample) | ||
| RU2470023C2 (ru) | 1-цианоциклопропильные производные в качестве ингибиторов катепсина к | |
| RU2016130932A (ru) | Производные хинолона как ингибиторы рецептора фактора роста фибробластов | |
| IL256375A (en) | New histological histories, process for their preparation and pharmaceutical preparations containing them | |
| JP2016515098A5 (enExample) | ||
| JP2010513523A5 (enExample) | ||
| JP2007523151A5 (enExample) | ||
| MX2010006364A (es) | Derivados de ftalazinona. | |
| RU2015148189A (ru) | ПРОИЗВОДНЫЕ 2-АМИДОПИРИДО[4, 3-d]ПИРИМИДИН-5-ОНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ WEE-1 | |
| JP2015511245A5 (enExample) | ||
| RU2009123930A (ru) | Химические соединения 637: пиридопиримидиндионы в качестве ингибиторов pde4 | |
| JP2013519707A5 (enExample) | ||
| RU2014130125A (ru) | Новые пиррольные соединения, способ их получения и фармацевтические композиции, содержащие их | |
| AU5364400A (en) | Use of CRF antagonists and related compositions | |
| HRP20150235T1 (hr) | Derivati pirimidina, njihovo dobivanje i njihova farmaceutska upotreba | |
| JP2014513139A5 (enExample) | ||
| JP2011500774A5 (enExample) | ||
| RU2016118753A (ru) | Производные пиридилкетона, способ их получения и их фармацевтическое применение | |
| JP2013537210A5 (enExample) | ||
| JP2017531648A5 (enExample) | ||
| JP2013529196A5 (enExample) | ||
| MXPA05000814A (es) | Inhibidores de quinasas. | |
| RU2017140446A (ru) | Гетероарильное производное или его фармацевтически приемлемая соль, способ их получения и фармацевтическая композиция для профилактики или лечения заболеваний, связанных с pi3 киназами, содержащая данное действующее вещество |